99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging
Anshul Gupta
1
,
Rashi Mathur
2
,
Sweta Singh
2
,
Narmada Bag
2
,
Urooj Khan
3
,
F Ahmad
1
,
Gamal A. Gabr
4, 5
,
Gaurav Jain
6
2
Division Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig SK Mazumdar Road, Delhi-110054, India.
|
3
Department of Pharmaceutics, B.S. Anangpuria Institute of Pharmacy, Faridabad 121004, India
|
5
6
Department of Pharmaceutics, Delhi Pharmaceutical Science and Research University, New Delhi-110017, India.
|
Publication type: Journal Article
Publication date: 2021-02-01
scimago Q1
wos Q2
SJR: 0.737
CiteScore: 7.2
Impact factor: 3.8
ISSN: 00223549, 15206017
PubMed ID:
33212161
Pharmaceutical Science
Abstract
Abstract
Methionine-gold nanoparticles (MGNs) was synthesized by conjugating methionine via dithiocarbamate linkage to gold nanoparticles (GNPs), prepared simultaneously by one pot modified Burst method. Formation of MGNs was confirmed by UV-visible spectroscopy and appearance of new IR bands in the range of 934 cm−1 to 1086 cm−1 and shifting of N-C,S-S and S-C-S stretching, confirms the involvement of ‘-S-C-S-' group of methionine dithiocarbamate with GNPs. The presence of Au in MGNs was confirmed by EDXA spectrum, whereas TEM, SAED and XRD revealed that MGNs are nanocrystalline (~13 nm) and have face-centered cubic structure. MGNs was labeled with 99mTc (TMGNs) with radiolabeling efficiency greater than 99% using 300 μg of stannous chloride, pH 7 and 90.6 MBq of 99mTcO4. The stability data showed that the conjugate will remain infrangible in systemic circulation and in acidic microenvironment of tumor. The blood kinetic profile of TMGN in rabbits and biodistribution studies in EAT tumor bearing balb/c mice showed longer in vivo circulation and slow clearance compared to radiolabeled methionine (TM). TMGN demonstrated nearly three-fold higher tumor accumulation (3.9 ± 0.35% ID/g), 2-fold lower tumor saturation dose (1.0 μg/kg) and higher tumor retention compared with TM. Data showed that the TMGN tumor: blood ratio (1.05) is nearly 2.5-fold higher than TM (0.44), whereas TMGN tumor: muscle ratio (97.5) is nearly 8-fold higher than TM (11.6). In conclusion, TMGN showed excellent tumor targeting and has promising prospects as a SPECT-radiopharmaceutical for imaging tumors.Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
Molecular Cancer
4 publications, 12.9%
|
|
|
International Journal of Pharmaceutics
2 publications, 6.45%
|
|
|
Journal of Drug Delivery Science and Technology
2 publications, 6.45%
|
|
|
Nanomaterials
1 publication, 3.23%
|
|
|
Pharmaceutics
1 publication, 3.23%
|
|
|
Frontiers in Bioengineering and Biotechnology
1 publication, 3.23%
|
|
|
Frontiers in Pharmacology
1 publication, 3.23%
|
|
|
Biomolecules
1 publication, 3.23%
|
|
|
Applied Nanoscience (Switzerland)
1 publication, 3.23%
|
|
|
Materials Today Advances
1 publication, 3.23%
|
|
|
Bioorganic Chemistry
1 publication, 3.23%
|
|
|
European Polymer Journal
1 publication, 3.23%
|
|
|
Dalton Transactions
1 publication, 3.23%
|
|
|
RSC Advances
1 publication, 3.23%
|
|
|
Journal of Biomaterials Science, Polymer Edition
1 publication, 3.23%
|
|
|
Critical Reviews in Food Science and Nutrition
1 publication, 3.23%
|
|
|
Springer Proceedings in Materials
1 publication, 3.23%
|
|
|
Nanoscale Advances
1 publication, 3.23%
|
|
|
Nuclear Engineering and Technology
1 publication, 3.23%
|
|
|
3 Biotech
1 publication, 3.23%
|
|
|
Russian Chemical Reviews
1 publication, 3.23%
|
|
|
Biomaterials Advances
1 publication, 3.23%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
12
|
|
|
Elsevier
11 publications, 35.48%
|
|
|
Springer Nature
8 publications, 25.81%
|
|
|
Royal Society of Chemistry (RSC)
4 publications, 12.9%
|
|
|
MDPI
3 publications, 9.68%
|
|
|
Frontiers Media S.A.
2 publications, 6.45%
|
|
|
Taylor & Francis
2 publications, 6.45%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
31
Total citations:
31
Citations from 2024:
9
(29.03%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Gupta A. et al. 99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging // Journal of Pharmaceutical Sciences. 2021. Vol. 110. No. 2. pp. 888-897.
GOST all authors (up to 50)
Copy
Gupta A., Mathur R., Singh S., Bag N., Khan U., Ahmad F., Gabr G. A., Kesharwani P., Jain G. 99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging // Journal of Pharmaceutical Sciences. 2021. Vol. 110. No. 2. pp. 888-897.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.xphs.2020.11.008
UR - https://doi.org/10.1016/j.xphs.2020.11.008
TI - 99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging
T2 - Journal of Pharmaceutical Sciences
AU - Gupta, Anshul
AU - Mathur, Rashi
AU - Singh, Sweta
AU - Bag, Narmada
AU - Khan, Urooj
AU - Ahmad, F
AU - Gabr, Gamal A.
AU - Kesharwani, Prashant
AU - Jain, Gaurav
PY - 2021
DA - 2021/02/01
PB - Elsevier
SP - 888-897
IS - 2
VL - 110
PMID - 33212161
SN - 0022-3549
SN - 1520-6017
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Gupta,
author = {Anshul Gupta and Rashi Mathur and Sweta Singh and Narmada Bag and Urooj Khan and F Ahmad and Gamal A. Gabr and Prashant Kesharwani and Gaurav Jain},
title = {99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging},
journal = {Journal of Pharmaceutical Sciences},
year = {2021},
volume = {110},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/j.xphs.2020.11.008},
number = {2},
pages = {888--897},
doi = {10.1016/j.xphs.2020.11.008}
}
Cite this
MLA
Copy
Gupta, Anshul, et al. “99mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging.” Journal of Pharmaceutical Sciences, vol. 110, no. 2, Feb. 2021, pp. 888-897. https://doi.org/10.1016/j.xphs.2020.11.008.